AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22986420 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone (MP)
Number of subjects: 48
Study 22986420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 48
Study 20400244 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus guideline and atlas for anorectal cancers (Group A)
Number of subjects: 14
Study 20400244 — intervention group
Group type: COMPARATOR
Intervention: No consensus guideline and atlas (Group B)
Number of subjects: 14
Study 19566621 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent-only intervention (n = 34)
Number of subjects: 93
Study 19566621 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family-based intervention (n = 33)
Number of subjects: 93
Study 19566621 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n = 26)
Number of subjects: 93
Study 17050227 — intervention group
Group type: EXPERIMENTAL
Intervention: QVAR alone
Number of subjects: 44
Study 15036395 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (21-session 7-week program consisting of 5x6 eccentric muscle actions at 60‐100% of concentric three maximal repetitions)
Number of subjects: 14
Study 15036395 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study 15036395 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (specifically at -30 degrees s(-1))
Number of subjects: 14
Study 11082781 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PCR-mediated amplification protocol for degraded ancient DNA
Number of subjects: 4
Study 8650814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin therapy
Number of subjects: 31
Study 8650814 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous fast‐acting insulin
Number of subjects: 31
Study 1401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural condition with broadband noise (interaural phase difference of 0 and pi) masking a 500-Hz probe tone (No pi S pi)
Number of subjects: 4
Study 1401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural condition with spectral power density of the masker 15 dB lower below or above the edge frequency (N pi oS pi)
Number of subjects: 4
Study 1401533 — intervention group
Group type: COMPARATOR
Intervention: Comparison of binaural and monaural conditions
Number of subjects: 4
Study 4009770 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-board technique
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Philadelphia collar
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Hare extrication collar
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Rigid plastic collar
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Philadelphia collar + short board
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Hare extrication collar + short board
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Rigid plastic collar + short board
Number of subjects: 97
Study 4009770 — intervention group
Group type: COMPARATOR
Intervention: Short board used alone
Number of subjects: 97
Study 3303937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis (intravenous initially, then oral if successful)
Number of subjects: 79
Study 3303937 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 79
Study 29288561 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen oral spray and ibuprofen
Number of subjects: 100
Study 29288561 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 100
Study 29141694 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary written by staff and family, given to the patient at ICU discharge or to the family in case of death.
Number of subjects: 700
Study 29141694 — intervention group
Group type: COMPARATOR
Intervention: Control group without any ICU diary.
Number of subjects: 700
Study 26387408 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai Massage (TTM)
Number of subjects: 30
Study 26387408 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest)
Number of subjects: 30
Study 24693632 — intervention group
Group type: COMPARATOR
Intervention: NaF (2% sodium fluoride solution)
Number of subjects: 24
Study 24693632 — intervention group
Group type: COMPARATOR
Intervention: Diode Laser (DL)
Number of subjects: 24
Study 24693632 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF-DL combination
Number of subjects: 24
Study 24693632 — intervention group
Group type: COMPARATOR
Intervention: HEMA-G (Gluma desensitizer)
Number of subjects: 24
Study 21813162 — intervention group
Group type: EXPERIMENTAL
Intervention: warfarin plus 75‐100 mg aspirin
Number of subjects: 1496
Study 21813162 — intervention group
Group type: COMPARATOR
Intervention: warfarin only
Number of subjects: 1496
Study 18714623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 cmH2O PEEP applied for 20 minutes, followed by 5 cmH2O PEEP for 20 minutes, then 10 cmH2O PEEP for 20 minutes (Group A)
Number of subjects: 30
Study 18714623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O PEEP applied and maintained for one hour (Group B)
Number of subjects: 30
Study 18714623 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP levels set in the opposite order to that of group A (Group C)
Number of subjects: 30
Study 16556753 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 60
Study 16556753 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 60
Study 12687839 — intervention group
Group type: COMPARATOR
Intervention: 8‐mm tip catheter
Number of subjects: 60
Study 12687839 — intervention group
Group type: EXPERIMENTAL
Intervention: irrigated tip catheter
Number of subjects: 60
Study 10781115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 80
Study 10781115 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 80
Study 10781115 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 80
Study 10781115 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide
Number of subjects: 80
Study 8814512 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 20 km and three 40 km time trials (TT) on an air-braked ergometry system (Kingcycle) (n = 6)
Number of subjects: 10
Study 8814512 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 40 km laboratory TT and two 40 km road TT competitions (n = 8)
Number of subjects: 10
Study 1428729 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DXR) incorporated into polyisohexylcyanoacrylate nanoparticles at 75 mg/m2
Number of subjects: 21
Study 1428729 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DXR) incorporated into polyisohexylcyanoacrylate nanoparticles
Number of subjects: 21
Study 3830930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (1 g with 10 g of CHO, three times a day, 30 min before meals)
Number of subjects: 8
Study 3830930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3830930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 8
Study 3830930 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 8
Study 31490194 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 0
Study 31490194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abdominal binder)
Number of subjects: 0
Study 29696666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)
Number of subjects: 91
Study 29696666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NS-0200 (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil)
Number of subjects: 91
Study 29696666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 27305855 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuNavi‐A system
Number of subjects: 56
Study 27305855 — intervention group
Group type: COMPARATOR
Intervention: Strker system
Number of subjects: 56
Study 25012707 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 402
Study 25012707 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge needle
Number of subjects: 402
Study 25012707 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropuncture (21-gauge needle) in specific subgroups
Number of subjects: 402
Study 25012707 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropuncture (21-gauge needle)
Number of subjects: 402
Study 22004983 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus placebo
Number of subjects: 22
Study 22004983 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex plus placebo
Number of subjects: 22
Study 22004983 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 22
Study 20143266 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI prior to NAC
Number of subjects: 74
Study 20143266 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI after completion of NAC
Number of subjects: 74
Study 18391631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin (including a maintenance regimen)
Number of subjects: 0
Study 18391631 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Number of subjects: 0
Study 18391631 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant versus adjuvant chemotherapy
Number of subjects: 0
Study 18391631 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens: Methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine and cisplatin
Number of subjects: 0
Study 18391631 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 0
Study 18391631 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent light
Number of subjects: 0
Study 15880333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 3010
Study 15880333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010
Study 15880333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3010
Study 11908598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoresin capsicum (OC) spray inhalation
Number of subjects: 35
Study 11908598 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 35
Study 11908598 — intervention group
Group type: COMPARATOR
Intervention: Oleoresin capsicum (OC) spray inhalation and Placebo
Number of subjects: 35
Study 9481626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement
Number of subjects: 8
Study 9481626 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic enzyme replacement
Number of subjects: 8
Study 8585252 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (mean 5.2 mg i.v.)
Number of subjects: 132
Study 8585252 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (mean 4.8 mg) plus pethidin (50 mg)
Number of subjects: 132
Study 2615928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of d-amphetamine sulfate
Number of subjects: 0
Study 2615928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 341945 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 46
Study 341945 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 46
Study 31331546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 270‐330 μg tablets three times a day for two months
Number of subjects: 80
Study 31331546 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study 29950814 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg (multiple doses)
Number of subjects: 48
Study 29950814 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (2.5-15 mg, single and multiple doses)
Number of subjects: 48
Study 29950814 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (10 mg, multiple doses)
Number of subjects: 48
Study 29950814 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (all doses)
Number of subjects: 48
Study 29950814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26405232 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb (bioresorbable vascular scaffold)
Number of subjects: 191
Study 26405232 — intervention group
Group type: COMPARATOR
Intervention: EES (durable polymer everolimus-eluting metallic stent)
Number of subjects: 191
Study 25261674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined neurolytic block of the celiac and superior hypogastric plexuses
Number of subjects: 52
Study 25261674 — intervention group
Group type: COMPARATOR
Intervention: Neurolytic celiac plexus block alone (NCPB group)
Number of subjects: 52
Study 22238097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 mg of cortisol (hydrocortisone)
Number of subjects: 0
Study 22238097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20831787 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 2746
Study 20831787 — intervention group
Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 2746
Study 20831787 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 2746
Study 17998771 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive diagnosis of Kawasaki disease
Number of subjects: 9965
Study 17998771 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography and routine echocardiography
Number of subjects: 9965
Study 17998771 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk students identified
Number of subjects: 9965
Study 16321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Added oils and fats intake
Number of subjects: 6572
Study 16321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oils with monounsaturated fatty acids (MUFA)
Number of subjects: 6572
Study 16321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal fat intake
Number of subjects: 6572
Study 16321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oils with polyunsaturated fatty acids or MUFA
Number of subjects: 6572
Study 12093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened persons for eligibility
Number of subjects: 172
Study 12093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible persons for participation
Number of subjects: 172
Study 12093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of screened persons who were eligible
Number of subjects: 172
Study 12093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of eligible persons who enrolled
Number of subjects: 172
Study 12093240 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening process
Number of subjects: 172
Study 9636831 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim)-supported FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) with ciprofloxacin prophylaxis; nine courses q three weeks; six different FEC dose levels used for treatment.
Number of subjects: 89
Study 7870397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative cholescintigraphy (QC)
Number of subjects: 34
Study 7870397 — intervention group
Group type: EXPERIMENTAL
Intervention: Common bile duct dynamics (CBDD)
Number of subjects: 34
Study 7870397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TAC and CBDD
Number of subjects: 34
Study 7870397 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive QC
Number of subjects: 34
Study 3348071 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 27
Study 3348071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31913967 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (25 sessions to the left dorsolateral prefrontal cortex)
Number of subjects: 40
Study 31913967 — intervention group
Group type: COMPARATOR
Intervention: ECT (4 to 8 sessions)
Number of subjects: 40
Study 29452970 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose‐glycerine‐castor oil (CGC)
Number of subjects: 18
Study 29452970 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 18
Study 29452970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl guar (HPG)
Number of subjects: 18
Study 29452970 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatments (CGC, CMC, HPG)
Number of subjects: 18
Study 29452970 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 27898071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis
Number of subjects: 40
Study 27898071 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 40
Study 26195541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored package (TP) sessions
Number of subjects: 206
Study 26195541 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 206
Study 22510538 — intervention group
Group type: COMPARATOR
Intervention: Morphine (60 mg/day)
Number of subjects: 70
Study 22510538 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (60 mg/day) + Pregabalin (25 mg/day to 150 mg/day over one week)
Number of subjects: 70
Study 20850270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleading invitation e-mail
Number of subjects: 569
Study 20850270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification e-mail
Number of subjects: 569
Study 20850270 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors published in 2006 or later
Number of subjects: 569
Study 20850270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification for authors with recent publications
Number of subjects: 569
Study 18080171 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.08 mg/kg/day)
Number of subjects: 30
Study 18080171 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (0.01-0.08 mg/kg/day)
Number of subjects: 30
Study 16497612 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg twice daily
Number of subjects: 75
Study 16497612 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice daily
Number of subjects: 75
Study 16497612 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg daily
Number of subjects: 75
Study 16497612 — intervention group
Group type: COMPARATOR
Intervention: naproxen 250 mg twice daily
Number of subjects: 75
Study 16497612 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 75
Study 12860541 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric external and concentric internal peak torques measured at 300 deg/sec in throwers' dominant limb
Number of subjects: 59
Study 12860541 — intervention group
Group type: COMPARATOR
Intervention: Eccentric external and concentric internal peak torques measured at 300 deg/sec in nonthrowers' dominant limb
Number of subjects: 59
Study 11119080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 4 ppm
Number of subjects: 10
Study 11119080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) with I:E of 1:3, 1:1, and 2:1
Number of subjects: 10
Study 11119080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IRV and INO
Number of subjects: 10
Study 9194508 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 42
Study 9194508 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 42
Study 9194508 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients after adjustment for blood pressure
Number of subjects: 42
Study 9194508 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BMI and mean BP
Number of subjects: 42
Study 7848156 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on peak flow monitoring (PFM)
Number of subjects: 352
Study 7848156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership of PEFM
Number of subjects: 352
Study 7848156 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management plan
Number of subjects: 352
Study 7848156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of PEFM
Number of subjects: 352
Study 7848156 — intervention group
Group type: EXPERIMENTAL
Intervention: Management decisions based on symptoms
Number of subjects: 352
Study 2457711 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-TPN
Number of subjects: 16
Study 31953188 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus neurolysis (EUS‐CPN)
Number of subjects: 48
Study 31953188 — intervention group
Group type: COMPARATOR
Intervention: Standard medicinal treatment using oxycodone and/or fentanyl
Number of subjects: 48
Study 30427696 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi and qigong (TCQ) training for 1 hour, three times per week for 12 weeks
Number of subjects: 50
Study 29169378 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Theme Elicitation (PTE) analysis
Number of subjects: 8
Study 29169378 — intervention group
Group type: COMPARATOR
Intervention: Researcher-led analysis
Number of subjects: 8
Study 24501355 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task with voluntary choice of more effortful alternative
Number of subjects: 0
Study 24501355 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task with forced-choice trials
Number of subjects: 0
Study 24501355 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-based decision-making task
Number of subjects: 0
Study 24501355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively challenging task voluntarily selected
Number of subjects: 0
Study 24501355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively challenging task externally imposed
Number of subjects: 0
Study 22784841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg orally)
Number of subjects: 87
Study 22784841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87